Impact of rotor ablation in non-paroxysmal AF patients: Findings from the per-protocol population of the OASIS trial at long-term follow-up

Sanghamitra Mohanty, Carola Gianni, Chintan Trivedi, Tamara Metz, Rong Bai, Amin Al-Ahmad, Shane Bailey, John David Burkhardt, G. Joseph Gallinghouse, Rodney Horton, Patrick M. Hranitzky, Javier E. Sanchez, Luigi Di Biase, Andrea Natale

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

The objective of this study was to evaluate the long-term efficacy of FIRM ablation with PVAI vs PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation in persistent (PeAF) and long-standing persistent AF (LSPAF) patients. The procedure time was recorded to be 180.6 ± 35.9 and 124.03 ± 45.4 minutes in the FIRM+PVI and PVI + PWI + non-PV trigger ablation group respectively. At 24-month follow-up, 24% (95% CI 8.7%–37.8%) in the FIRM-ablation group and 48% (95% CI 27.6–63.3%) in the non-PV trigger ablation group remained arrhythmia-free off-antiarrhythmic drugs after a single procedure. Clinical Trial Registration: ClinicalTrials.gov (Identifier: NCT02533843).

Original languageEnglish (US)
Pages (from-to)145-148
Number of pages4
JournalAmerican Heart Journal
Volume205
DOIs
StatePublished - Nov 1 2018
Externally publishedYes

Fingerprint

Anti-Arrhythmia Agents
Population
Cardiac Arrhythmias
Clinical Trials
poly(divinyl-co-N-vinylpyrrolidinone)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of rotor ablation in non-paroxysmal AF patients : Findings from the per-protocol population of the OASIS trial at long-term follow-up. / Mohanty, Sanghamitra; Gianni, Carola; Trivedi, Chintan; Metz, Tamara; Bai, Rong; Al-Ahmad, Amin; Bailey, Shane; Burkhardt, John David; Gallinghouse, G. Joseph; Horton, Rodney; Hranitzky, Patrick M.; Sanchez, Javier E.; Di Biase, Luigi; Natale, Andrea.

In: American Heart Journal, Vol. 205, 01.11.2018, p. 145-148.

Research output: Contribution to journalLetter

Mohanty, S, Gianni, C, Trivedi, C, Metz, T, Bai, R, Al-Ahmad, A, Bailey, S, Burkhardt, JD, Gallinghouse, GJ, Horton, R, Hranitzky, PM, Sanchez, JE, Di Biase, L & Natale, A 2018, 'Impact of rotor ablation in non-paroxysmal AF patients: Findings from the per-protocol population of the OASIS trial at long-term follow-up', American Heart Journal, vol. 205, pp. 145-148. https://doi.org/10.1016/j.ahj.2018.05.021
Mohanty, Sanghamitra ; Gianni, Carola ; Trivedi, Chintan ; Metz, Tamara ; Bai, Rong ; Al-Ahmad, Amin ; Bailey, Shane ; Burkhardt, John David ; Gallinghouse, G. Joseph ; Horton, Rodney ; Hranitzky, Patrick M. ; Sanchez, Javier E. ; Di Biase, Luigi ; Natale, Andrea. / Impact of rotor ablation in non-paroxysmal AF patients : Findings from the per-protocol population of the OASIS trial at long-term follow-up. In: American Heart Journal. 2018 ; Vol. 205. pp. 145-148.
@article{5bd226276f6143e7814289145b3f9de3,
title = "Impact of rotor ablation in non-paroxysmal AF patients: Findings from the per-protocol population of the OASIS trial at long-term follow-up",
abstract = "The objective of this study was to evaluate the long-term efficacy of FIRM ablation with PVAI vs PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation in persistent (PeAF) and long-standing persistent AF (LSPAF) patients. The procedure time was recorded to be 180.6 ± 35.9 and 124.03 ± 45.4 minutes in the FIRM+PVI and PVI + PWI + non-PV trigger ablation group respectively. At 24-month follow-up, 24{\%} (95{\%} CI 8.7{\%}–37.8{\%}) in the FIRM-ablation group and 48{\%} (95{\%} CI 27.6–63.3{\%}) in the non-PV trigger ablation group remained arrhythmia-free off-antiarrhythmic drugs after a single procedure. Clinical Trial Registration: ClinicalTrials.gov (Identifier: NCT02533843).",
author = "Sanghamitra Mohanty and Carola Gianni and Chintan Trivedi and Tamara Metz and Rong Bai and Amin Al-Ahmad and Shane Bailey and Burkhardt, {John David} and Gallinghouse, {G. Joseph} and Rodney Horton and Hranitzky, {Patrick M.} and Sanchez, {Javier E.} and {Di Biase}, Luigi and Andrea Natale",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ahj.2018.05.021",
language = "English (US)",
volume = "205",
pages = "145--148",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Impact of rotor ablation in non-paroxysmal AF patients

T2 - Findings from the per-protocol population of the OASIS trial at long-term follow-up

AU - Mohanty, Sanghamitra

AU - Gianni, Carola

AU - Trivedi, Chintan

AU - Metz, Tamara

AU - Bai, Rong

AU - Al-Ahmad, Amin

AU - Bailey, Shane

AU - Burkhardt, John David

AU - Gallinghouse, G. Joseph

AU - Horton, Rodney

AU - Hranitzky, Patrick M.

AU - Sanchez, Javier E.

AU - Di Biase, Luigi

AU - Natale, Andrea

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The objective of this study was to evaluate the long-term efficacy of FIRM ablation with PVAI vs PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation in persistent (PeAF) and long-standing persistent AF (LSPAF) patients. The procedure time was recorded to be 180.6 ± 35.9 and 124.03 ± 45.4 minutes in the FIRM+PVI and PVI + PWI + non-PV trigger ablation group respectively. At 24-month follow-up, 24% (95% CI 8.7%–37.8%) in the FIRM-ablation group and 48% (95% CI 27.6–63.3%) in the non-PV trigger ablation group remained arrhythmia-free off-antiarrhythmic drugs after a single procedure. Clinical Trial Registration: ClinicalTrials.gov (Identifier: NCT02533843).

AB - The objective of this study was to evaluate the long-term efficacy of FIRM ablation with PVAI vs PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation in persistent (PeAF) and long-standing persistent AF (LSPAF) patients. The procedure time was recorded to be 180.6 ± 35.9 and 124.03 ± 45.4 minutes in the FIRM+PVI and PVI + PWI + non-PV trigger ablation group respectively. At 24-month follow-up, 24% (95% CI 8.7%–37.8%) in the FIRM-ablation group and 48% (95% CI 27.6–63.3%) in the non-PV trigger ablation group remained arrhythmia-free off-antiarrhythmic drugs after a single procedure. Clinical Trial Registration: ClinicalTrials.gov (Identifier: NCT02533843).

UR - http://www.scopus.com/inward/record.url?scp=85053152630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053152630&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2018.05.021

DO - 10.1016/j.ahj.2018.05.021

M3 - Letter

C2 - 30144981

AN - SCOPUS:85053152630

VL - 205

SP - 145

EP - 148

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -